{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:15:49Z","timestamp":1792696549343,"version":"4.5.0"},"reference-count":418,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>This review provides a comprehensive account of 30 natural product (NP)-inspired antifungal therapeutic agents introduced for human use between 1872 and August 2026. These comprise 14 NPs (47%) and 16 NP-derived (NP-D; 53%) agents, the latter encompassing semisynthetic derivatives and synthetic analogues of NP scaffolds. These antifungal drugs are organised into eight structural classes, many of which share modes of action (MoA), and are individually classified as NP or NP-D, with accompanying structures illustrating the chemical modifications that link NP-D agents to their progenitor NPs. We summarise the first introduction or approval of each agent for human use by country and year, documented antifungal spectrum, routes of administration, usage status, MoA and key historical, chemical and clinical context. Analysis of the assembled dataset documents the historical importance and enduring clinical impact of these agents, while also revealing a recent concentration of approvals among NP-D inhibitors of \u03b2-1,3-D-glucan synthase. These findings underscore the enduring value of NPs as antifungal leads and highlight the need for greater chemical and mechanistic diversity in antifungal discovery, particularly through agents directed at new fungal targets.<\/jats:p>","DOI":"10.3390\/antibiotics15090938","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:28:43Z","timestamp":1790090923000},"page":"938","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Natural Product-Inspired Antifungal Drugs Introduced for Human Use from 1872 to August 2026"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6689-4236","authenticated-orcid":false,"given":"Mark S.","family":"Butler","sequence":"first","affiliation":[{"name":"Institute for Molecular Bioscience, University of Queensland, Brisbane 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-7754","authenticated-orcid":false,"given":"Robert J.","family":"Capon","sequence":"additional","affiliation":[{"name":"Institute for Molecular Bioscience, University of Queensland, Brisbane 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e200430","DOI":"10.1590\/0074-02760200430","article-title":"Invasive fungal disease in humans: Are we aware of the real impact?","volume":"115","author":"Firacative","year":"2020","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Rodrigues, M.L., and Nosanchuk, J.D. (2020). Fungal diseases as neglected pathogens: A wake-up call to public health officials. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0007964"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/mlf2.12036","article-title":"Assessing global fungal threats to humans","volume":"1","author":"Xu","year":"2022","journal-title":"mLife"},{"key":"ref_5","unstructured":"GBD 2019 Antimicrobial Resistance Collaborators (2022). Global mortality associated with 33 bacterial pathogens in 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 400, 2221\u20132248."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41579-023-00960-9","article-title":"The rapid emergence of antifungal-resistant human-pathogenic fungi","volume":"21","author":"Lockhart","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40588-024-00219-8","article-title":"Emerging antifungal resistance in fungal pathogens","volume":"11","author":"Hui","year":"2024","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s44259-024-00055-2","article-title":"A one health roadmap towards understanding and mitigating emerging Fungal Antimicrobial Resistance: fAMR","volume":"2","author":"Fisher","year":"2024","journal-title":"npj Antimicrob. Resist."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2885.2003.00456.x","article-title":"Antifungal agents of use in animal health\u2014Chemical, biochemical and pharmacological aspects","volume":"26","author":"Bossche","year":"2003","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2885.2003.00457.x","article-title":"Antifungal agents of use in animal health\u2014Practical applications","volume":"26","author":"Rochette","year":"2003","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15449","DOI":"10.1021\/acs.jmedchem.0c01502","article-title":"A structural analysis of the FDA Green Book-approved veterinary drugs and roles in human medicine","volume":"63","author":"Scott","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Guerrero, J.J.G., De Leon, M.P., Cena-Navarro, R.B., Notarte, K.I.R., Balendres, M.A.O., and dela Cruz, T.E.E. (2026). Veterinary mycology: Challenges and applications. Mycology in a Changing Planet: Applications and Perspectives from Southeast Asia, Springer.","DOI":"10.1007\/978-981-95-2640-6"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acsinfecdis.4c00530","article-title":"Challenges and opportunities with antibiotic discovery and exploratory research","volume":"10","author":"Piddock","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"(2025). High time to tackle drug-resistant fungal infections. Nature, 640, 569.","DOI":"10.1038\/d41586-025-01177-x"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00142-23","DOI":"10.1128\/cmr.00142-23","article-title":"Advancements and challenges in antifungal therapeutic development","volume":"37","author":"Puumala","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"a019588","DOI":"10.1101\/cshperspect.a019588","article-title":"Evolutionary perspectives on human fungal pathogens","volume":"5","author":"Taylor","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Vanreppelen, G., Wuyts, J., Van Dijck, P., and Vandecruys, P. (2023). Sources of antifungal drugs. J. Fungi, 9.","DOI":"10.3390\/jof9020171"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s44259-023-00007-2","article-title":"Molecular mechanisms governing antifungal drug resistance","volume":"1","author":"Lee","year":"2023","journal-title":"npj Antimicrob. Resist."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101331","DOI":"10.1016\/j.lanmic.2025.101331","article-title":"WHO assessment of the preclinical antifungal pipeline: Evaluating innovation and preparedness in the face of emerging fungal threats","volume":"7","author":"Gigante","year":"2026","journal-title":"Lancet Microbe"},{"key":"ref_20","first-page":"36","article-title":"Eczematoid ringworm of the extremities and groins: Addresses introductory to a discussion on the subject","volume":"5","author":"Whitfield","year":"1912","journal-title":"Proc. R. Soc. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/archderm.1920.02350060067010","article-title":"Whitfield\u2019s Ointment","volume":"1","author":"Whitfield","year":"1920","journal-title":"Arch. Derm. Syphilol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/bmj.2.4937.453","article-title":"The Whitfield tradition of therapy","volume":"2","author":"Williams","year":"1955","journal-title":"Br. Med. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0733-8635(18)30954-9","article-title":"Anthralin and coal tar therapy for psoriasis","volume":"2","author":"Lowe","year":"1984","journal-title":"Dermatol. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/0190-9622(92)70232-5","article-title":"History of the treatment of psoriasis","volume":"27","author":"Farber","year":"1992","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","first-page":"1","article-title":"150 years of croton oil research","volume":"25","year":"1969","journal-title":"Experientia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/jpp\/rgac040","article-title":"Botany, traditional uses, phytochemistry, pharmacological and toxicological effects of Croton tiglium Linn.: A comprehensive review","volume":"74","author":"Zhang","year":"2022","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Greenwood, D. (2008). The poor relations: Fungi and viruses. Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph, Oxford University Press.","DOI":"10.1093\/oso\/9780199534845.001.0001"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1039\/D5NP00067J","article-title":"Natural product inspired antibiotics approved for human use\u20141943 to 2025","volume":"43","author":"Butler","year":"2026","journal-title":"Nat. Prod. Rep."},{"key":"ref_29","unstructured":"Butler, M.S., and Capon, R.J. (Antibiotics, 2026). Synthetic antifungal drugs introduced for human use from 1872 to September 2026, Antibiotics, Manuscript in preparation."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/acs.jnatprod.5c01368","article-title":"The role of natural product chemistry in drug discovery: Two decades of progress and perspectives","volume":"89","author":"Butler","year":"2026","journal-title":"J. Nat. Prod."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1461-0248.2004.00576.x","article-title":"Biogeographical variation in community response to root allelochemistry: Novel weapons and exotic invasion","volume":"7","author":"Vivanco","year":"2004","journal-title":"Ecol. Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/BF01517113","article-title":"\u00dcber Derivate der Cinchonins\u00e4ure und des Chinolins","volume":"1","author":"Weidel","year":"1880","journal-title":"Monatsh. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/cber.188101401289","article-title":"Oxychinolin aus Chinolinsulfos\u00e4ure","volume":"14","author":"Bedall","year":"1881","journal-title":"Ber. Dtsch. Chem. Ges."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1042\/bj0410534","article-title":"The choice of a chelating agent for inactivating trace metals: II. Derivatives of oxine (8-hydroxyquinoline)","volume":"41","author":"Albert","year":"1947","journal-title":"Biochem. J."},{"key":"ref_35","unstructured":"Royal Society of Chemistry (2026, September 11). The Merck Index Online. Available online: https:\/\/merckindex.rsc.org\/."},{"key":"ref_36","first-page":"40","article-title":"Compilation of new drugs 1940 thru 1975","volume":"42","year":"1976","journal-title":"Pharm. Times"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"William Andrew Publishing (2007). Pharmaceutical Manufacturing Encyclopedia. Third Edition. Volume 1: A Through B, William Andrew Publishing.","DOI":"10.1016\/B978-0-8155-1526-5.50024-6"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"William Andrew Publishing (2007). Pharmaceutical Manufacturing Encyclopedia. Third Edition. Volume 2: C Through G, William Andrew Publishing.","DOI":"10.1016\/B978-0-8155-1526-5.50016-7"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"William Andrew Publishing (2007). Pharmaceutical Manufacturing Encyclopedia. Third Edition. Volume 3: H Through P, William Andrew Publishing.","DOI":"10.1016\/B978-0-8155-1526-5.50016-7"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"William Andrew Publishing (2007). Pharmaceutical Manufacturing Encyclopedia. Third Edition. Volume 4: Q Through Z, William Andrew Publishing.","DOI":"10.1016\/B978-0-8155-1526-5.50016-7"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0065-7743(02)37027-1","article-title":"To market, to market\u20142001","volume":"Volume 37","author":"Doherty","year":"2002","journal-title":"Annual Reports in Medicinal Chemistry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0065-7743(03)38034-0","article-title":"To market, to market\u20142002","volume":"Volume 38","author":"Doherty","year":"2003","journal-title":"Annual Reports in Medicinal Chemistry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0065-7743(07)42032-2","article-title":"To market, to market\u20142006","volume":"Volume 42","author":"Macor","year":"2007","journal-title":"Annual Reports in Medicinal Chemistry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1021\/mc-2022-vol57.ch24","article-title":"To market, to market\u20132021: Small molecules","volume":"Volume 57","author":"Rudolph","year":"2022","journal-title":"2022 Medicinal Chemistry Reviews"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/mc-2024-vol59.ch19","article-title":"To market, to market\u20142023: Small molecules","volume":"Volume 59","author":"Rudolph","year":"2024","journal-title":"2024 Medicinal Chemistry Reviews"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.drudis.2018.09.006","article-title":"Lost medicines: A longer view of the pharmaceutical industry with the potential to reinvigorate discovery","volume":"24","author":"Kinch","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_47","first-page":"296","article-title":"The evolution of the drug laws of the United States, 1906\u20131964","volume":"19","author":"Yakowitz","year":"1964","journal-title":"Food Drug Cosmet. Law J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/jch.12012","article-title":"The 50th anniversary of the Kefauver-Harris amendments: Efficacy assessment and the randomized clinical trial","volume":"14","author":"Turner","year":"2012","journal-title":"J. Clin. Hypertens."},{"key":"ref_49","unstructured":"World Health Organization (2026, August 20). The Selection and Use of Essential Medicines, 2025: WHO Model List of Essential Medicines, 24th List. Available online: https:\/\/www.who.int\/publications\/i\/item\/B09474."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"He, Q., Sun, Y., Chen, X., Feng, J., and Liu, Y. (2023). Benzoin resin: An overview on its production process, phytochemistry, traditional use and quality control. Plants, 12.","DOI":"10.3390\/plants12101976"},{"key":"ref_51","unstructured":"Wood, H.C. (1884). Benzoinum\u2014Benzoin. U.S. A Treatise on Therapeutics: Comprising Materia Medica and Toxicology, with Especial Reference to the Application of the Physiological Action of Drugs to Clinical Medicine, J.B. Lippincott & Co.. [5th ed.]."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2018.10.008","article-title":"The first 3500 years of aspirin history from its roots\u2014A concise summary","volume":"113","author":"Montinari","year":"2019","journal-title":"Vasc. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.2.3012.309","article-title":"Discussion on fungous infections of the glabrous skin","volume":"2","author":"Adamson","year":"1913","journal-title":"Br. Med. J."},{"key":"ref_54","first-page":"47","article-title":"Bromsalicyl-Chloranilid-Soventol, ein Beitrag zur Therapie behandlungserschwerter Epidermophytosen","volume":"18","author":"Ruther","year":"1955","journal-title":"Z. Haut. Geschlechtskr."},{"key":"ref_55","first-page":"104","article-title":"Halogenated hydroxybenzoates as antimycotics","volume":"10","author":"Korger","year":"1960","journal-title":"Arzneimittel-Forschung"},{"key":"ref_56","unstructured":"PDMA (2026, March 31). The Standards Marketing Approval of Athlete\u2019s Foot and Ringworm Remedies (Notification PSB No.447, May 15, 1998). Available online: https:\/\/www.pmda.go.jp\/files\/000272501.pdf."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e2025007","DOI":"10.5620\/eaht.2025007","article-title":"A critical review on the journey of benzoic acid in the pharmaceutical industry from manufacturing processes through various uses to disposal: An environmental perspective","volume":"40","author":"Issa","year":"2025","journal-title":"Environ. Anal. Health Toxicol."},{"key":"ref_58","first-page":"373","article-title":"Ueber ein neues Anilid der salicyligen S\u00e4ure","volume":"CXIV","author":"Schischkoff","year":"1860","journal-title":"Ann. Chem. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"T245","DOI":"10.1080\/19447023008661518","article-title":"16\u2014The inhibitory action of certain substances on the growth of mould fungi","volume":"21","author":"Fargher","year":"1930","journal-title":"J. Text. Inst. Trans."},{"key":"ref_60","unstructured":"Torgeson, D.C. (1967). Application and use of fungicides as industrial preservatives. Agricultural and Industrial Applications Environmental Interactions, Academic Press."},{"key":"ref_61","first-page":"28","article-title":"Treatment of superficial fungus infections in routine dermatologic practice","volume":"69","author":"Rees","year":"1948","journal-title":"Calif. Med."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"(1950). New Drugs and Instruments. Postgrad. Med., 8, 344-A-53.","DOI":"10.1080\/00325481.1950.11694021"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Johnson, J.R. (2011). The Perkin reaction and related reactions. Organic Reactions, John Wiley & Sons.","DOI":"10.1002\/0471264180.or001.08"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1039\/JS8682100181","article-title":"XXIII.\u2014On the hydride of aceto-salicyl","volume":"21","author":"Perkin","year":"1868","journal-title":"J. Chem. Soc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/cber.190003302154","article-title":"Ueber die gebromten Cumarine und einige Derivate derselben","volume":"33","author":"Simonis","year":"1900","journal-title":"Ber. Dtsch. Chem. Ges."},{"key":"ref_66","first-page":"545","article-title":"Action sur les microbes des substances ph\u00e9noliques. II","volume":"25","author":"Delauney","year":"1937","journal-title":"J. Pharm. Chim."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.105.2729.409","article-title":"Action of substituted salicylaldehydes on bacteria and fungi","volume":"105","author":"Felton","year":"1947","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/jps.2600501006","article-title":"Synthesis and germicidal activity of halogenated salicylanilides and related compounds","volume":"50","author":"Lemaire","year":"1961","journal-title":"J. Pharm. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"(1949). Information Service. J. Am. Pharm. Assoc. (Pract. Pharm. Ed.), 10, 114\u2013116.","DOI":"10.1016\/S0095-9561(16)31755-8"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archotol.1952.00710020261002","article-title":"Otitis externa\u2014A controversial subject","volume":"56","author":"Tremble","year":"1952","journal-title":"AMA Arch. Otolaryngol."},{"key":"ref_71","unstructured":"(2026, March 12). Federal Register (Monday, April 30, 1984), p 18357, Available online: https:\/\/www.govinfo.gov\/content\/pkg\/FR-1984-04-30\/pdf\/FR-1984-04-30.pdf."},{"key":"ref_72","first-page":"548","article-title":"Chemotherapeutische Wirksamkeit von halogenierten Salicylaniliden in Abh\u00e4ngigkeit von der Konstitution","volume":"4","author":"Kraushaar","year":"1954","journal-title":"Arzneim.-Forsch."},{"key":"ref_73","first-page":"1048","article-title":"Werks\u00e4rztliche Prophylaxe und Behandlung der Mykose mit Multifungin","volume":"101","author":"Unsold","year":"1959","journal-title":"Munch. Med. Wochenschr."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0536.1986.tb05290.x","article-title":"Allergic contact dermatitis to bromsalicylchloranilide","volume":"14","author":"Buckley","year":"1986","journal-title":"Contact Dermat."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0021-9673(01)86999-5","article-title":"Simultaneous determination of bromochlorosalicylanilide and bamipine in pharmaceutical formulations by high-performance liquid chromatography","volume":"362","author":"Kountourellis","year":"1986","journal-title":"J. Chromatogr. A"},{"key":"ref_76","unstructured":"(1960). Neue Arzneimittel. Schweiz. Apoth. Ztg., 98, 806\u2013814."},{"key":"ref_77","first-page":"18142","article-title":"Neue Arzneimittel","volume":"132","author":"Gerecke","year":"1961","journal-title":"Chem. Zentralbl."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/jid.1964.155","article-title":"Photo cross-sensitization among halogen-hydroxybenzoic acid derivatives","volume":"43","author":"Fregert","year":"1964","journal-title":"J. Investig. Dermatol."},{"key":"ref_79","first-page":"456","article-title":"Antifungal activity of a new group of salicylamide derivatives for dermatophytes. I. In vitro activity of N-butyl-3-phenyl salicylamide","volume":"6","author":"Hok","year":"1956","journal-title":"Antibiot. Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.1956.01550110048012","article-title":"Treatment of cutaneous fungus infections with a phenylsalicylamide derivative","volume":"74","author":"Keddie","year":"1956","journal-title":"AMA Arch. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/jid.1956.87","article-title":"Butylphenamide; A new anti-fungal agent: Preliminary studies","volume":"27","author":"Krafchuk","year":"1956","journal-title":"J. Investig. Dermatol."},{"key":"ref_82","first-page":"79","article-title":"Clinical trial of butylphenamide in the treatment of certain varieties of ringworm","volume":"27","author":"Beare","year":"1958","journal-title":"Ulst. Med. J."},{"key":"ref_83","unstructured":"FDA (2026, March 31). List of Drug Master Files (DMFs) (DMF 419 Butylphenamide), Available online: https:\/\/www.fda.gov\/drugs\/drug-master-files-dmfs\/list-drug-master-files-dmfs."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.2042-7158.1952.tb13220.x","article-title":"The analgesic and antipyretic properties of some derivatives of salicylamide","volume":"4","author":"Bavin","year":"1952","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.2042-7158.1957.tb12347.x","article-title":"The preparation and antifungal activity of some salicylic acid derivatives","volume":"9","author":"Coates","year":"1957","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_86","unstructured":"Simmonite, D., and Tattersall, K. (1961). Improvements in Fungicidal and\/or Fungistatic Compositions. (GB872891A)."},{"key":"ref_87","unstructured":"Katori, T., Sato, G., and Makino, S. (1974). Hexyloxybenzamide Solution. (JP49062620A)."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3314\/jjmm1960.24.222","article-title":"In vitro antifungal activities of antifungal agents against clinical isolates. A survey on the strains of dermatophytes","volume":"24","author":"Kusunoki","year":"1983","journal-title":"Jpn. J. Med. Mycol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1346-8138.1984.tb01477.x","article-title":"Comparison of the in vitro antifungal activities of clotrimazole, miconazole, econazole and exalamide against clinical isolates of dermatophytes","volume":"11","author":"Kusunoki","year":"1984","journal-title":"J. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/BF02670027","article-title":"Two new stable polybrominated salicylanilides for antibacterial use in soap and detergent products","volume":"41","author":"Molnar","year":"1964","journal-title":"J. Am. Oil Chem. Soc."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1600-0781.2010.00494.x","article-title":"Photoallergic contact dermatitis","volume":"26","author":"Kerr","year":"2010","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1440-0960.1967.tb01297.x","article-title":"Photo-allergic contact dermatitis from halogenated phenolic compounds","volume":"9","author":"Burry","year":"1967","journal-title":"Australas. J. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1039\/C6AY00916F","article-title":"Determination of seven restricted halogenated salicylanilides in cosmetics by high performance liquid chromatography","volume":"8","author":"Li","year":"2016","journal-title":"Anal. Methods"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0163-7258(82)90064-X","article-title":"The biology and toxicology of molluscicides, Bayluscide","volume":"19","author":"Andrews","year":"1982","journal-title":"Pharmacol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Biersack, B. (2024). The antifungal potential of niclosamide and structurally related salicylanilides. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115977"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mmy\/myy027","article-title":"Repurposing the anthelminthic salicylanilide oxyclozanide against susceptible and clinical resistant Candida albicans strains","volume":"57","author":"Pic","year":"2018","journal-title":"Med. Mycol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Rajamuthiah, R., Fuchs, B.B., Conery, A.L., Kim, W., Jayamani, E., Kwon, B., Ausubel, F.M., and Mylonakis, E. (2015). Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124595"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archderm.1948.01520200059008","article-title":"Salicylanilide therapy in tinea capitis","volume":"58","author":"Felsher","year":"1948","journal-title":"Arch. Derm. Syphilol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.1038\/s41598-018-29973-8","article-title":"A phenotypic small-molecule screen identifies halogenated salicylanilides as inhibitors of fungal morphogenesis, biofilm formation and host cell invasion","volume":"8","author":"Garcia","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Sutar, Y., Nabeela, S., Singh, S., Alqarihi, A., Solis, N., Ghebremariam, T., Filler, S., Ibrahim, A.S., Date, A., and Uppuluri, P. (2022). Niclosamide-loaded nanoparticles disrupt Candida biofilms and protect mice from mucosal candidiasis. PLoS Biol., 20.","DOI":"10.1371\/journal.pbio.3001762"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1039\/jr9630000168","article-title":"24. The mechanism of the antibacterial action of phenols and salicylaldehydes. Part I","volume":"166","author":"Clarke","year":"1963","journal-title":"J. Chem. Soc."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1039\/jr9640002458","article-title":"462. The mechanism of the antibacterial action of phenols and salicylaldehydes. Part III. Substituted benzaldehydes","volume":"167","author":"Burton","year":"1964","journal-title":"J. Chem. Soc."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1039\/jr9650000438","article-title":"68. The mechanism of the antibacterial action of phenols and salicylaldehydes. Part IV. Substituted salicylaldehydes","volume":"168","author":"Burton","year":"1965","journal-title":"J. Chem. Soc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1515\/znc-2007-7-806","article-title":"Antimicrobial properties of substituted salicylaldehydes and related compounds","volume":"62","author":"Pelttari","year":"2007","journal-title":"Z. Naturforsch. C"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ejmech.2015.01.041","article-title":"Correlation of the antimicrobial activity of salicylaldehydes with broadening of the NMR signal of the hydroxyl proton. Possible involvement of proton exchange processes in the antimicrobial activity","volume":"92","author":"Elo","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"17178","DOI":"10.1002\/anie.201811650","article-title":"Affinity enhancement of protein ligands by reversible covalent modification of neighboring lysine residues","volume":"57","author":"Catalano","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.tips.2023.04.007","article-title":"Protein-protein interactions: Developing small-molecule inhibitors\/stabilizers through covalent strategies","volume":"44","author":"Lucero","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"101941","DOI":"10.1016\/j.rechem.2024.101941","article-title":"Schiff bases and their possible therapeutic applications: A review","volume":"13","author":"Nidhi","year":"2025","journal-title":"Results Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"9426","DOI":"10.3390\/molecules17089426","article-title":"Antifungal activity of salicylanilides and their esters with 4-(trifluoromethyl)benzoic acid","volume":"17","year":"2012","journal-title":"Molecules"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1021\/acs.jnatprod.7b00821","article-title":"Light-induced transformation of the aromatic heptaene antifungal antibiotic candicidin D into its all-trans isomer","volume":"81","author":"Szczeblewski","year":"2018","journal-title":"J. Nat. Prod."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Szczeblewski, P., G\u00f3rska, J., Andra\u0142oj\u0107, W., Janke, P., W\u0105sik, K., and Laskowski, T. (2021). Iso-partricin, an aromatic analogue of amphotericin B: How shining light on old drugs might help create new ones. Antibiotics, 10.","DOI":"10.3390\/antibiotics10091102"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Haro-Reyes, T., D\u00edaz-Peralta, L., Galv\u00e1n-Hern\u00e1ndez, A., Rodr\u00edguez-L\u00f3pez, A., Rodr\u00edguez-Fragoso, L., and Ortega-Blake, I. (2022). Polyene antibiotics physical chemistry and their effect on lipid membranes; impacting biological processes and medical applications. Membranes, 12.","DOI":"10.3390\/membranes12070681"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ps.1712","article-title":"Nanodisks protect amphotericin B from ultraviolet light and oxidation-induced damage","volume":"65","author":"Tufteland","year":"2009","journal-title":"Pest. Manag. Sci."},{"key":"ref_114","first-page":"A62","article-title":"Panel discussion on candidiasis","volume":"11","author":"Donomae","year":"1958","journal-title":"J. Antibiot."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/mgmj.mgmj_12_21","article-title":"Novel active pharmaceutical ingredients from India: The actors-Part-I","volume":"8","author":"Ghosh","year":"2021","journal-title":"MGM J. Med. Sci."},{"key":"ref_116","unstructured":"(2026, February 17). The Chemist and Druggist (February 6, 1965), Guide to New Medicaments, p. 138. Available online: https:\/\/archive.org\/details\/b19974760M4627\/page\/138\/mode\/2up."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"7774","DOI":"10.1002\/chem.200900292","article-title":"Fifty years of chemical research at Farmitalia","volume":"15","author":"Arcamone","year":"2009","journal-title":"Chem. Eur. J."},{"key":"ref_118","first-page":"309","article-title":"Evaluation of the antifungal antibiotic etruscomycin [Japanese]","volume":"14","author":"Kawabe","year":"1966","journal-title":"Chemotherapy"},{"key":"ref_119","first-page":"608","article-title":"In vitro studies with a new antimycotic agent: Lucensomycin","volume":"12","author":"Graessle","year":"1962","journal-title":"Antibiot. Chemother."},{"key":"ref_120","first-page":"409","article-title":"Mepartricin: A new antifungal agent for the treatment of disseminated Candida infections in the immunocompromised host","volume":"69","author":"Bacigalupo","year":"1983","journal-title":"Acta Haematol."},{"key":"ref_121","unstructured":"(2026, February 18). Refdata Website. PENTACIN Ovula 3 mg 10 Stk. Available online: https:\/\/sai.refdata.ch\/detail\/21708."},{"key":"ref_122","unstructured":"Reuter, K., Meier, V., Stolz, F., Krimmer, D., and Winnips, C. (2013). Highly Pure Pentamycin. (EP2271655B1)."},{"key":"ref_123","first-page":"1125","article-title":"Protective action of fungicidin (nystatin) in mice against virulence enhancing activity of oxytetracycline on Candida albicans","volume":"3","author":"Hazen","year":"1953","journal-title":"Antibiot. Chemother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/00275514.1976.12019977","article-title":"Elizabeth Lee Hazen: 1885\u20131975","volume":"68","author":"Bacon","year":"1976","journal-title":"Mycologia"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Busch-Vishniac, I., Busch, L., and Tietjen, J.S. (2024). Elizabeth Lee Hazen and Rachel Fuller Brown. Women in the National Inventors Hall of Fame: The First 50 Years, Springer Nature.","DOI":"10.1007\/978-3-031-75526-2"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0040-4039(01)94502-2","article-title":"Polyene antifungal antibiotics: \u03b1 and \u03b2 glycosidic structures in lucensomycin and nystatin","volume":"19","author":"Boicelli","year":"1978","journal-title":"Tetrahedron Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3181\/00379727-76-18397","article-title":"Fungicidin, an antibiotic produced by a soil actinomycete","volume":"76","author":"Hazen","year":"1951","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_128","first-page":"1673","article-title":"The structure of nystatin A2","volume":"79","author":"Pawlak","year":"2005","journal-title":"Pol. J. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"171702","DOI":"10.1016\/j.cej.2025.171702","article-title":"Screening of nystatin high-yielding recombinant strains in response to spaceflight and elucidation of digitoxose biosynthesis","volume":"527","author":"Li","year":"2026","journal-title":"Chem. Eng. J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.7164\/antibiotics.41.1289","article-title":"The structure of nystatin A3, a component of nystatin complex","volume":"41","author":"Zielinski","year":"1988","journal-title":"J. Antibiot."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/synbio2010003","article-title":"Generation of new glycoanalogues of polyene antibiotics by synthetic biology\u2014Testing current technical boundaries","volume":"2","author":"Hogan","year":"2024","journal-title":"SynBio"},{"key":"ref_132","first-page":"454","article-title":"Identification of two major components in Chinese nystatin","volume":"21","author":"Ling","year":"1986","journal-title":"Acta Pharm. Sin."},{"key":"ref_133","first-page":"83","article-title":"Separation, identification, and renaming of the main component of Chinese nystatin","volume":"12","author":"Ma","year":"1987","journal-title":"Chin. J. Antibiot."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Liu, X., Zhuo, J., Chen, Z., Zhang, Y., Jiang, W., and Guan, R. (2026). Research and application of the polyene macrolide antibiotic nystatin. Molecules, 31.","DOI":"10.3390\/molecules31020330"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1016\/S0040-4039(00)96962-4","article-title":"Macrolide antibiotic studies. XVI. The structure of nystatin","volume":"11","author":"Chong","year":"1970","journal-title":"Tetrahedron Lett."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1016\/S0040-4039(01)80734-6","article-title":"Complete stereostructure of nystatin A1: A proton NMR study","volume":"30","author":"Lancelin","year":"1989","journal-title":"Tetrahedron Lett."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00253-004-1802-4","article-title":"Biosynthesis of the polyene macrolide antibiotic nystatin in Streptomyces noursei","volume":"67","author":"Zotchev","year":"2005","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"108185","DOI":"10.1016\/j.jbc.2025.108185","article-title":"Crystal structure of cytochrome P450 NysL and the structural basis for stereo- and regio-selective oxidation of antifungal macrolides","volume":"301","author":"Murarka","year":"2025","journal-title":"J. Biol. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.synbio.2024.05.012","article-title":"Digitoxose as powerful glycosyls for building multifarious glycoconjugates of natural products and un-natural products","volume":"9","author":"Li","year":"2024","journal-title":"Synth. Syst. Biotechnol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Grayson, M.L. (2017). Nystatin. Kucers\u2019 The Use of Antibiotics, CRC Press. [7th ed.].","DOI":"10.1128\/9781498747950"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Rai, A., Misra, S.R., Panda, S., Sokolowski, G., Mishra, L., Das, R., and Lapinska, B. (2022). Nystatin effectiveness in oral candidiasis treatment: A systematic review & meta-analysis of clinical trials. Life, 12.","DOI":"10.3390\/life12111677"},{"key":"ref_142","unstructured":"Mayo Clinic (2026, March 02). Nystatin (Topical Route). Available online: https:\/\/www.mayoclinic.org\/drugs-supplements\/nystatin-topical-route\/description\/drg-20065134."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1378\/chest.54.Supplement_1.296","article-title":"The discovery and development of amphotericin B","volume":"54","author":"Dutcher","year":"1968","journal-title":"Dis. Chest"},{"key":"ref_144","unstructured":"(2026, April 14). The Chemist and Druggist (April 15, 1995), BMS Deletions, p. 600. Available online: https:\/\/archive.org\/details\/b19974760M6229\/mode\/2up."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Homei, A., and Worboys, M. (2013). Candida: A disease of antibiotics. Fungal Disease in Britain and the United States 1850\u20132000: Mycoses and Modernity, Palgrave Macmillan.","DOI":"10.26530\/OAPEN_474551"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1128\/br.37.2.166-196.1973","article-title":"Chemistry and biology of the polyene macrolide antibiotics","volume":"37","year":"1973","journal-title":"Bacteriol. Rev."},{"key":"ref_147","unstructured":"(2026, July 31). The Chemist and Druggist (October 8, 1960), This Week\u2019s Changes, p. 452. Available online: https:\/\/archive.org\/details\/b19974760M4392\/page\/n33\/mode\/2up."},{"key":"ref_148","unstructured":"New York Times (2026, April 14). F.D.A. Orders Ban on 49 Antibiotics; Combination Drugs Faulted\u201421 Companies Involved (p 21, 13 June 1969). Available online: https:\/\/www.nytimes.com\/1969\/06\/13\/archives\/fda-orders-ban-on-49-antibiotics-combination-drugs-faulted-21.html."},{"key":"ref_149","unstructured":"Time (2026, April 14). The FDA: Cleaning Out the Medicine Chest (25 July 1969). Available online: https:\/\/time.com\/archive\/6637224\/the-fda-cleaning-out-the-medicine-chest\/."},{"key":"ref_150","unstructured":"(2026, April 14). Justia Website. E.r. Squibb and Sons, Inc., Petitioner, v. Otis R. Bowen, M.d., Secretary of Health & Human Services; et al., Respondents, 870 F.2d 678 (D.C. Cir. 1989). Available online: https:\/\/law.justia.com\/cases\/federal\/appellate-courts\/F2\/870\/678\/311870\/."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1128\/jb.85.2.436-439.1963","article-title":"Streptomyces nodosus sp. N., the amphotericin-producing organism","volume":"85","author":"Trejo","year":"1963","journal-title":"J. Bacteriol."},{"key":"ref_152","first-page":"566","article-title":"A new antifungal antibiotic, amphotericin B","volume":"3","author":"Oura","year":"1956","journal-title":"Antibiot. Annu."},{"key":"ref_153","first-page":"574","article-title":"Amphotericins A and B: Two new antifungal antibiotics possessing high activity against deep-seated and superficial mycoses","volume":"3","author":"Jambor","year":"1956","journal-title":"Antibiot. Annu."},{"key":"ref_154","first-page":"579","article-title":"Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies","volume":"3","author":"Donovick","year":"1956","journal-title":"Antibiot. Annu."},{"key":"ref_155","first-page":"587","article-title":"Amphotericins A and B, antifungal antibiotics produced by a streptomycete. II. The isolation and properties of the crystalline amphotericins","volume":"3","author":"Stiller","year":"1956","journal-title":"Antibiot. Annu."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1021\/ja01575a070","article-title":"The structure of mycosamine","volume":"79","author":"Walters","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1016\/S0040-4039(01)98612-5","article-title":"Structure and absolute configuration of the polyene macrolide antibiotic amphotericin B","volume":"11","author":"Mechlinski","year":"1970","journal-title":"Tetrahedron Lett."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7164\/antibiotics.38.175","article-title":"The structure of amphotericin A II. The complete structure of the antibiotic","volume":"38","author":"Sowinski","year":"1985","journal-title":"J. Antibiot."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7164\/antibiotics.49.1232","article-title":"Stereostructure of amphotericin A","volume":"49","author":"Sowinski","year":"1996","journal-title":"J. Antibiot."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Grayson, M.L. (2017). Amphotericin B deoxycholate. Kucers\u2019 The Use of Antibiotics, CRC Press. [7th ed.].","DOI":"10.1128\/9781498747950"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1056\/NEJMra2412565","article-title":"Mucormycosis","volume":"394","author":"Kontoyiannis","year":"2026","journal-title":"N. Eng. J. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/14787210.2018.1528872","article-title":"Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis","volume":"16","author":"Keane","year":"2018","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1038\/s41564-024-01854-z","article-title":"Acquired amphotericin B resistance leads to fitness trade-offs that can be mitigated by compensatory evolution in Candida auris","volume":"9","author":"Carolus","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jgar.2020.12.016","article-title":"Advances in Fusarium drug resistance research","volume":"24","author":"Zhao","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"103247","DOI":"10.1016\/j.fgb.2019.103247","article-title":"Antifungal resistance in Aspergillus terreus: A current scenario","volume":"131","year":"2019","journal-title":"Fungal Genet. Biol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00431-007-0527-7","article-title":"Fungal infections in primary immunodeficiencies","volume":"166","author":"Antachopoulos","year":"2007","journal-title":"Eur. J. Pediatr."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of amphotericin B: An overview of the main antifungal agent used to treat invasive fungal infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Grayson, M.L. (2017). Liposomal amphotericin B. Kucers\u2019 The Use of Antibiotics, CRC Press. [7th ed.].","DOI":"10.1128\/9781498747950"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/jac\/dkac352","article-title":"Liposomal amphotericin B\u2014The present","volume":"77","author":"Maertens","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Grayson, M.L. (2017). Amphotericin B lipid complex (ABLC). Kucers\u2019 The Use of Antibiotics, CRC Press. [7th ed.].","DOI":"10.1128\/9781498747950"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clinthera.2024.01.011","article-title":"Effectiveness, tolerability, and safety of different amphotericin B formulations in invasive fungal infections: A multicenter, retrospective, observational study","volume":"46","author":"Cavassin","year":"2024","journal-title":"Clin. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: A comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/515085","article-title":"Food and Drug Administration approval of AmBisome (Liposomal Amphotericin B) for treatment of visceral leishmaniasis","volume":"28","author":"Meyerhoff","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"106661","DOI":"10.1016\/j.actatropica.2022.106661","article-title":"Amphotericin B: A drug of choice for Visceral Leishmaniasis","volume":"235","author":"Kumari","year":"2022","journal-title":"Acta Trop."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Fr\u00e9zard, F., Aguiar, M.M.G., Ferreira, L.A.M., Ramos, G.S., Santos, T.T., Borges, G.S.M., Vallejos, V.M.R., and De Morais, H.L.O. (2023). Liposomal amphotericin B for treatment of leishmaniasis: From the identification of critical physicochemical attributes to the design of effective topical and oral formulations. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010099"},{"key":"ref_176","first-page":"505","article-title":"Trichomycin, a new antibiotic produced by Streptomyces hachijoensis with trichomonadicidal and anti-fungal activity","volume":"22","author":"Hosoya","year":"1952","journal-title":"Jpn. J. Exp. Med."},{"key":"ref_177","unstructured":"The Ministry of Health, Labour and Welfare (2026, February 16). The Japanese Pharmacopoeia, Available online: https:\/\/www.mhlw.go.jp\/content\/11120000\/000945683.pdf."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"778","DOI":"10.7164\/antibiotics.43.778","article-title":"Trichomycin B, a polyene macrolide from Streptomyces","volume":"43","author":"Komori","year":"1990","journal-title":"J. Antibiot."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"904","DOI":"10.7164\/antibiotics.43.904","article-title":"Trichomycin A, a heptaene macrolide: Isolation and characterization","volume":"43","author":"Komori","year":"1990","journal-title":"J. Antibiot."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"44862","DOI":"10.1038\/s41598-025-28626-x","article-title":"Isolation, structure revision and stereochemistry of trichomycins A and B, aromatic analogues of amphotericin B","volume":"15","author":"Laskowski","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_181","first-page":"1","article-title":"Hamycin. Isolation of a new heptaene, hamycin X","volume":"6","author":"Bhate","year":"1963","journal-title":"Hindustan Antibiot. Bull."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1128\/am.15.1.43-48.1967","article-title":"Countercurrent distribution studies on hamycin","volume":"15","author":"Ganguli","year":"1967","journal-title":"Appl. Microbiol."},{"key":"ref_183","unstructured":"Pandey, R.C., and Rinehart, K.L. (1976, January 27\u201329). Structural studies on hamycin A, an antifungal heptaene antibiotic. Proceedings of the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, USA."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7164\/antibiotics.30.158","article-title":"Polyene antibiotics. IX. An improved method for the preparation of methyl esters of polyene antibiotics","volume":"30","author":"Pandey","year":"1977","journal-title":"J. Antibiot."},{"key":"ref_185","first-page":"136","article-title":"Hamycin. I. Discovery and biological studies","volume":"3","author":"Thimmalachar","year":"1961","journal-title":"Hindustan Antibiot. Bull."},{"key":"ref_186","first-page":"139","article-title":"Hamycin. II. Isolation and chemical properties","volume":"3","author":"Bhate","year":"1961","journal-title":"Hindustan Antibiot. Bull."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1039\/C7MB00112F","article-title":"New insights into polyene macrolide biosynthesis in Couchioplanes caeruleus","volume":"13","author":"Sheehan","year":"2017","journal-title":"Mol. Biosyst."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1039\/C39770000710","article-title":"Structural elucidation of heptaene macrolide antibiotics 67\u2013121-A and 67\u2013121-C","volume":"13","author":"Wright","year":"1977","journal-title":"J. Chem. Soc. Chem. Commun."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"911","DOI":"10.7164\/antibiotics.35.911","article-title":"N-Aminoacyl derivatives of polyene macrolide antibiotics and their esters","volume":"35","author":"Wright","year":"1982","journal-title":"J. Antibiot."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1271\/bbb.120961","article-title":"Versatility of enzymes catalyzing late steps in polyene 67-121C biosynthesis","volume":"77","author":"Stephens","year":"2013","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"ref_191","unstructured":"Hindustan Antibiotics Ltd (2026, February 13). Webpage. Milestones. Available online: http:\/\/hindantibiotics.in\/?page_id=16."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/00275514.1953.12024259","article-title":"Candicidin, a new antifungal antibiotic","volume":"45","author":"Lechevalier","year":"1953","journal-title":"Mycologia"},{"key":"ref_193","first-page":"219","article-title":"Candicidin and other polyenic antifungal antibiotics","volume":"33","author":"Waksman","year":"1965","journal-title":"Bull. World Health Organ."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3181\/00379727-82-20128","article-title":"In vitro and in vivo activity of candicidin on pathogenic fungi","volume":"82","author":"Kligman","year":"1953","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/ja.2015.17","article-title":"The stereostructure of candicidin D","volume":"68","author":"Szwarc","year":"2015","journal-title":"J. Antibiot."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"40158","DOI":"10.1038\/srep40158","article-title":"Analytical studies on ascosin, candicidin and levorin multicomponent antifungal antibiotic complexes. The stereostructure of ascosin A2","volume":"7","author":"Szczeblewski","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mrc.4229","article-title":"The structure, including stereochemistry, of levorin A1","volume":"53","author":"Szwarc","year":"2015","journal-title":"Magn. Reson. Chem."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Caffrey, P., Hogan, M., and Song, Y. (2022). New glycosylated polyene macrolides: Refining the ore from genome mining. Antibiotics, 11.","DOI":"10.3390\/antibiotics11030334"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1080\/14786419.2019.1596095","article-title":"The complete stereochemistry of the antibiotic candicidin A3 (syn. ascosin A3, levorin A3)","volume":"34","author":"Szczeblewski","year":"2020","journal-title":"Nat. Prod. Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"114971","DOI":"10.1016\/j.jpba.2022.114971","article-title":"Effect of mobile phase pH on liquid chromatography retention of mepartricin related compounds and impurities as support to the structural investigation by liquid chromatography\u2013mass spectrometry","volume":"220","author":"Tengattini","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/BF01957888","article-title":"Partricin methyl ester, a semisynthetic polyene antibiotic","volume":"28","author":"Bruzzese","year":"1972","journal-title":"Experientia"},{"key":"ref_202","unstructured":"Bruzzese, T., and Ferrari, R. (1973). Partricin. (US3773925A)."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/(SICI)1097-0045(19981101)37:3<187::AID-PROS8>3.0.CO;2-T","article-title":"Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH","volume":"37","author":"Lowe","year":"1998","journal-title":"Prostate"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.urology.2003.08.006","article-title":"Role of mepartricin in category III chronic nonbacterial prostatitis\/chronic pelvic pain syndrome: A randomized prospective placebo-controlled trial","volume":"63","author":"Gallo","year":"2004","journal-title":"Urology"},{"key":"ref_205","first-page":"984","article-title":"Binding of mepartricin to sex hormones, a key factor of its activity on benign prostatic hyperplasia","volume":"51","author":"Barone","year":"2001","journal-title":"Arzneimittel-Forschung"},{"key":"ref_206","first-page":"878","article-title":"Pimaricin, a new antifungal antibiotic","volume":"5","author":"Struyk","year":"1957","journal-title":"Antibiot. Annu."},{"key":"ref_207","first-page":"538","article-title":"Pimaricin, ein Antibioticum gegen Pilze und Trichomonaden","volume":"17","author":"Raab","year":"1967","journal-title":"Arzneimittel-Forschung"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1749-6632.1960.tb20149.x","article-title":"Tennecetin","volume":"89","author":"Welsh","year":"1960","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1128\/AEM.00099-13","article-title":"Improvement of natamycin production by engineering of phosphopantetheinyl transferases in Streptomyces chattanoogensis L10","volume":"79","author":"Jiang","year":"2013","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1016\/S0040-4039(01)82827-6","article-title":"The structure of the macrolide antibiotic pimaricin","volume":"7","author":"Golding","year":"1966","journal-title":"Tetrahedron Lett."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.7164\/antibiotics.29.1035","article-title":"Polyene antibiotics. VII. Carbon-13 nuclear magnetic resonance evidence for cyclic hemiketals in the polyene antibiotics amphotericin B, nystatin A1, tetrin A, tetrin B, lucensomycin, and pimaricin","volume":"29","author":"Pandey","year":"1976","journal-title":"J. Antibiot."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1021\/ja00166a065","article-title":"Stereostructure of pimaricin","volume":"112","author":"Lancelin","year":"1990","journal-title":"J. Am. Chem. Soc."},{"key":"ref_213","unstructured":"(2026, February 17). The Chemist and Druggist (September 6, 1969), Guide to New Medicaments, p. 218. Available online: https:\/\/archive.org\/details\/b19974760M4876\/mode\/2up."},{"key":"ref_214","unstructured":"(2026, February 17). The Chemist and Druggist (March 16, 1974), Prescription Specialties, p. 292. Available online: https:\/\/archive.org\/details\/b19974760M5112\/mode\/2up."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Grayson, M.L. (2017). Natamycin. Kucers\u2019 The Use of Antibiotics, CRC Press. [7th ed.].","DOI":"10.1128\/9781498747950"},{"key":"ref_216","unstructured":"(1979). Natamycin approved\u2014First U.S. drug for fungal keratitis. FDA Drug Bull., 8, 37\u201338."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11046-024-00874-x","article-title":"Fusarium keratitis: A systematic review (1969 to 2023)","volume":"189","author":"Cintra","year":"2024","journal-title":"Mycopathologia"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/ICO.0000000000003559","article-title":"Overview of mycotic keratitis","volume":"43","author":"Arboleda","year":"2024","journal-title":"Cornea"},{"key":"ref_219","unstructured":"Batt, C.A., and Tortorello, M.L. (2014). Permitted preservatives\u2014Natamycin. Encyclopedia of Food Microbiology, Academic Press. [2nd ed.]."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10068-021-00981-1","article-title":"Natamycin: A natural preservative for food applications\u2014A review","volume":"30","author":"Meena","year":"2021","journal-title":"Food Sci. Biotechnol."},{"key":"ref_221","first-page":"119","article-title":"La etruscomycina, nuovo antibiotico antifungino prodotto dallo Streptomyces lucensis n.sp","volume":"4","author":"Arcamone","year":"1957","journal-title":"G. Microbiol."},{"key":"ref_222","first-page":"345","article-title":"Isolamento e caratterizzazione di un nuovo antibiotico: La etruscomicina","volume":"49","author":"Arcamone","year":"1959","journal-title":"Ann. Chim."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1016\/S0040-4039(01)82828-8","article-title":"The structure of lucensomycin. Part I","volume":"7","author":"Gaudiano","year":"1966","journal-title":"Tetrahedron Lett."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1016\/S0040-4039(01)82829-X","article-title":"The structure of lucensomycin. Part II","volume":"7","author":"Gaudiano","year":"1966","journal-title":"Tetrahedron Lett."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1016\/S0040-4039(01)85167-4","article-title":"Macrolide antibiotic studies. XVII. Cyclic hemiketal structures in nystatin, amphotericin B, pimaricin and lucensomycin","volume":"13","author":"Chong","year":"1972","journal-title":"Tetrahedron Lett."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1134\/S107042721209025X","article-title":"Synthesis, antifungal and antiviral activity of hydrophosphoryl derivatives of lucensomycin","volume":"85","author":"Belakhov","year":"2012","journal-title":"Russ. J. Appl. Chem."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1134\/S1070363216030129","article-title":"Application of the Todd\u2013Atherton synthetic approach for chemical modification of tetraene macrolide antibiotic lucensomycin","volume":"86","author":"Belakhov","year":"2016","journal-title":"Russ. J. Gen. Chem."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11094-016-1412-3","article-title":"Synthesis and antifungal and antiviral activity of N-benzyl derivatives of the tetraene macrolide antibiotic lucensomycin","volume":"50","author":"Belakhov","year":"2016","journal-title":"Pharm. Chem. J."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/nchembio.2188","article-title":"Polyketide and nonribosomal peptide retro-biosynthesis and global gene cluster matching","volume":"12","author":"Dejong","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1038\/s41598-024-57888-0","article-title":"Isolation of Streptomyces inhibiting multiple-phytopathogenic fungi and characterization of lucensomycin biosynthetic gene cluster","volume":"14","author":"Park","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1038\/s41598-021-82934-6","article-title":"Eliciting the silent lucensomycin biosynthetic pathway in Streptomyces cyanogenus S136 via manipulation of the global regulatory gene adpA","volume":"11","author":"Yushchuk","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1021\/acscentsci.1c00148","article-title":"Sterol sponge mechanism is conserved for glycosylated polyene macrolides","volume":"7","author":"Guo","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"ref_233","first-page":"716","article-title":"Fungichromin and fungichromatin: New polyene antifungal agents","volume":"2","author":"Tytell","year":"1955","journal-title":"Antibiot. Annu."},{"key":"ref_234","first-page":"719","article-title":"Effects of oils and fatty acids on the production of fungichromin","volume":"2","author":"McCarthy","year":"1955","journal-title":"Antibiot. Annu."},{"key":"ref_235","unstructured":"Dhar, M.L., Thaller, V., and Whiting, M.C. (1960). The structures of lagosin and filipin. Proc. Chem. Soc., 301\u2013302."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/jr9640000842","article-title":"160. Researches on polyenes. Part VIII. The structures of lagosin and filipin","volume":"167","author":"Dhar","year":"1964","journal-title":"J. Chem. Soc."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1021\/ja00870a031","article-title":"Fungichromin: Complete structure and absolute configuration at C26 and C27","volume":"84","author":"Cope","year":"1962","journal-title":"J. Am. Chem. Soc."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"988","DOI":"10.7164\/antibiotics.35.988","article-title":"Physicochemical and biological comparison of polyene macrolide antibiotics fungichromin, lagosin and cogomycin","volume":"35","author":"Pandey","year":"1982","journal-title":"J. Antibiot."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1021\/ja00217a041","article-title":"Biosynthesis and full NMR assignment of fungichromin, a polyene antibiotic from Streptomyces cellulosae","volume":"110","author":"Noguchi","year":"1988","journal-title":"J. Am. Chem. Soc."},{"key":"ref_240","unstructured":"Gottlieb, D., and Ammann, A. (1965). Antibiotic Filipin. (US3188272)."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/anie.199512271","article-title":"Relative and absolute configuration of filipin III","volume":"34","author":"Rychnovsky","year":"1995","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1351\/pac198961030427","article-title":"Studies directed towards the stereoselective synthesis of polyene macrolide antibiotics","volume":"61","author":"Oishi","year":"1989","journal-title":"Pure Appl. Chem."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"10974","DOI":"10.1021\/jacs.3c03011","article-title":"Total synthesis of pentamycin by a conformationally biased double Stille ring closure with a trienyl-bis-stannane","volume":"145","author":"Babczyk","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/ja.2005.71","article-title":"Absolute configuration of TPU-0043, a pentaene macrolide from Streptomyces sp.","volume":"58","author":"Igarashi","year":"2005","journal-title":"J. Antibiot."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1021\/acschembio.9b00270","article-title":"Pentamycin biosynthesis in Philippine Streptomyces sp. S816: Cytochrome P450-catalyzed installation of the C-14 hydroxyl group","volume":"14","author":"Zhou","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1007\/s00253-023-12672-4","article-title":"Enhancement of fungichromin production of Streptomyces sp. WP-1 by genetic engineering","volume":"107","author":"Wan","year":"2023","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_247","unstructured":"BioSpace (2026, February 18). Lumavita AG Announces Marketing Authorisation for Pentamycin in Switzerland (27 August 2009). Available online: https:\/\/www.biospace.com\/lumavita-ag-announces-marketing-authorisation-for-pentamycin-in-switzerland."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000316329","article-title":"Safety, tolerability and pharmacokinetics of intravaginal pentamycin","volume":"56","author":"Bitzer","year":"2010","journal-title":"Chemotherapy"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1074\/jbc.M707821200","article-title":"Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane","volume":"283","author":"Souza","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"100102","DOI":"10.1016\/j.bbadva.2023.100102","article-title":"Natamycin interferes with ergosterol-dependent lipid phases in model membranes","volume":"4","author":"Akkerman","year":"2023","journal-title":"BBA Adv."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"184350","DOI":"10.1016\/j.bbamem.2024.184350","article-title":"Ergosterol promotes aggregation of natamycin in the yeast plasma membrane","volume":"1866","author":"Szomek","year":"2024","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.15.5.716","article-title":"Classification of polyene antibiotics according to chemical structure and biological effects","volume":"15","author":"Medoff","year":"1979","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1128\/AAC.18.2.226","article-title":"Classification of polyene antibiotics according to their synergistic effect in combination with bleomycin A2 or fusidic acid","volume":"18","author":"Akiyama","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41594-021-00685-4","article-title":"Fungicidal amphotericin B sponges are assemblies of staggered asymmetric homodimers encasing large void volumes","volume":"28","author":"Lewandowska","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Carolus, H., Pierson, S., Lagrou, K., and Van Dijck, P. (2020). Amphotericin B and other polyenes\u2014Discovery, clinical use, mode of action and drug resistance. J. Fungi, 6.","DOI":"10.3390\/jof6040321"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41586-023-06710-4","article-title":"Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal","volume":"623","author":"Maji","year":"2023","journal-title":"Nature"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41598-023-28036-x","article-title":"Antibiotic-sterol interactions provide insight into the selectivity of natural aromatic analogues of amphotericin B and their photoisomers","volume":"13","author":"Czub","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jddst.2017.07.015","article-title":"Current perspectives on natamycin in ocular fungal infections","volume":"41","author":"Patil","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1007\/s12325-023-02541-x","article-title":"Natamycin ocular delivery: Challenges and advancements in ocular therapeutics","volume":"40","author":"Mascarenhas","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ophtha.2014.03.004","article-title":"Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis","volume":"121","author":"Sun","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_261","doi-asserted-by":"crossref","unstructured":"Tanwar, S., Kalra, S., and Bari, V.K. (2024). Insights into the role of sterol metabolism in antifungal drug resistance: A mini-review. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1409085"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1042\/bj0330240","article-title":"Studies in the biochemistry of micro-organisms: Griseofulvin, C17H17O6Cl, a metabolic product of Penicillium griseo-fulvum Dierckx","volume":"33","author":"Oxford","year":"1939","journal-title":"Biochem. J."},{"key":"ref_263","first-page":"219","article-title":"The structure of griseofulvin","volume":"11","author":"Grove","year":"1951","journal-title":"Chem. Ind."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1039\/jr9520003949","article-title":"759. Griseofulvin. Part I","volume":"155","author":"Grove","year":"1952","journal-title":"J. Chem. Soc."},{"key":"ref_265","doi-asserted-by":"crossref","unstructured":"MacMillan, J. (1959). 361. Griseofulvin. Part XIV. Some alcoholytic reactions and the absolute configuration of griseofulvin. J. Chem. Soc., 1823\u20131830.","DOI":"10.1039\/jr9590001823"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1039\/jr9630001050","article-title":"193. Fungal metabolites. Part I. The stereochemistry of griseofulvin: X-ray analysis of 5-bromogriseofulvin","volume":"166","author":"Brown","year":"1963","journal-title":"J. Chem. Soc."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0007-1536(46)80042-1","article-title":"A substance causing abnormal development of fungal hyphae produced by Penicillium janczewskii zal.: I. Biological assay, production and isolation of \u2018curling factor\u2019","volume":"29","author":"Brian","year":"1946","journal-title":"Trans. Br. Mycol. Soc."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0007-1536(49)80033-7","article-title":"A substance causing abnormal development of fungal hyphae produced by Penicillium janczewskii Zal: III. Identity of \u2018curling factor\u2019 with griseofulvin","volume":"32","author":"Brian","year":"1949","journal-title":"Trans. Br. Mycol. Soc."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(58)92363-8","article-title":"Oral treatment of ringworm with griseofulvin","volume":"272","author":"Williams","year":"1958","journal-title":"Lancet"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2133.1959.tb13379.x","article-title":"The treatment of ringworm with griseofulvin","volume":"71","author":"Gentles","year":"1959","journal-title":"Br. J. Dermatol."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.2042-7158.1962.tb11082.x","article-title":"Some factors influencing the absorption of griseofulvin from the gastrointestinal tract","volume":"14","author":"Duncan","year":"1962","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.2042-7158.1985.tb05065.x","article-title":"Fat contents of meals and bioavailability of griseofulvin in man","volume":"37","author":"Ogunbona","year":"1985","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40262-025-01511-6","article-title":"The impact of dietary interventions on the pharmacokinetics of antifungal drugs: A systematic review with meta-analyses","volume":"64","author":"Zagrodzki","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"ref_274","doi-asserted-by":"crossref","unstructured":"Grayson, M.L. (2017). Griseofulvin. Kucers\u2019 The Use of Antibiotics, CRC Press. [7th ed.].","DOI":"10.1128\/9781498747950"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40257-024-00848-1","article-title":"Expert panel review of skin and hair dermatophytoses in an era of antifungal resistance","volume":"25","author":"Hill","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14787210.2024.2405936","article-title":"Now that griseofulvin is not available, what to do with tinea capitis treatments?","volume":"22","author":"Bonifaz","year":"2024","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1039\/qr9631700001","article-title":"Griseofulvin","volume":"17","author":"Grove","year":"1963","journal-title":"Q. Rev. Chem. Soc."},{"key":"ref_278","unstructured":"(2026, January 30). The Chemist and Druggist (March 28, 1959), New Products, p. 332. Available online: https:\/\/archive.org\/details\/b19974760M4309\/page\/n33\/mode\/2up."},{"key":"ref_279","unstructured":"(2026, January 30). The Chemist and Druggist (April 4, 1959), New Products, p. 359. Available online: https:\/\/archive.org\/details\/b19974760M4310\/page\/358\/mode\/2up."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"12088","DOI":"10.1021\/cr400368e","article-title":"The chemistry of griseofulvin","volume":"114","author":"Petersen","year":"2014","journal-title":"Chem. Rev."},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Aris, P., Wei, Y., Mohamadzadeh, M., and Xia, X. (2022). Griseofulvin: An updated overview of old and current knowledge. Molecules, 27.","DOI":"10.3390\/molecules27207034"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0190-9622(90)70287-R","article-title":"Problems of resistant dermatophytes","volume":"23","author":"Jones","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11046-008-9110-7","article-title":"Antifungal resistance mechanisms in dermatophytes","volume":"166","author":"Peres","year":"2008","journal-title":"Mycopathologia"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1574-6968.2007.00710.x","article-title":"Analysis of Trichophyton rubrum gene expression in response to cytotoxic drugs","volume":"271","author":"Segato","year":"2007","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_285","doi-asserted-by":"crossref","unstructured":"Martinez-Rossi, N.M., Peres, N.T.A., Bitencourt, T.A., Martins, M.P., and Rossi, A. (2021). State-of-the-art dermatophyte infections: Epidemiology aspects, pathophysiology, and resistance mechanisms. J. Fungi, 7.","DOI":"10.3390\/jof7080629"},{"key":"ref_286","first-page":"489","article-title":"Morphology of griseofulvin-resistant isolates of Mongolian variant of Trichophyton schoenleini","volume":"103","author":"Zheng","year":"1990","journal-title":"Chin. Med. J."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/jdv.20810","article-title":"Trichophyton indotineae: Epidemiology, antifungal resistance and antifungal stewardship strategies","volume":"40","author":"Gupta","year":"2026","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"e70048","DOI":"10.1111\/myc.70048","article-title":"Therapeutic outcomes in patients with Trichophyton indotineae: A systematic review and meta-analysis of individual patient data","volume":"68","author":"Leeyaphan","year":"2025","journal-title":"Mycoses"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1021\/ja01166a008","article-title":"Analogs of aspergillic acid. IV. Substituted 2-bromopyridine-N-oxides and their conversion to cyclic thiohydroxamic acids","volume":"72","author":"Shaw","year":"1950","journal-title":"J. Am. Chem. Soc."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3181\/00379727-82-20041","article-title":"In vitro studies with 1-hydroxy-2(1H)-pyridinethione","volume":"82","author":"Pansy","year":"1953","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15563657808988226","article-title":"Toxicity of pyrithiones","volume":"13","author":"Black","year":"1978","journal-title":"Clin. Toxicol."},{"key":"ref_292","unstructured":"(2026, June 29). Head and Shoulders History. Available online: https:\/\/headandshoulders.com\/en-us\/about\/our-history."},{"key":"ref_293","unstructured":"(2026, June 08). Medicament Website. FONDERMA 1%, Solution. Available online: https:\/\/medicament.ma\/medicament\/fonderma-1-solution\/."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0041-008X(77)90049-7","article-title":"Percutaneous penetration of the magnesium sulfate adduct of dipyrithione in man","volume":"41","author":"Wedig","year":"1977","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_295","first-page":"73","article-title":"The analysis of 2,2\u2032-dithiobis-pyridine-1,1\u2032-dioxide and related compounds in clear antidandruff shampoos via reverse-phase liquid chromatography","volume":"30","author":"Fenn","year":"1979","journal-title":"J. Soc. Cosmet. Chem."},{"key":"ref_296","unstructured":"Swissmedic (2026, June 08). Swissmedic Journal 8\/2005, Crimanex, Shampoo and Crimanex, Tinktur, p. 615. Available online: https:\/\/www.swissmedic.ch\/dam\/swissmedic\/fr\/dokumente\/stab\/journal\/swissmedic_journal082005.pdf.download.pdf\/swissmedic_journal082005.pdf."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2133.2011.10571.x","article-title":"The antifungal mechanism of action of zinc pyrithione","volume":"165","author":"Reeder","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1128\/AAC.00724-11","article-title":"Zinc pyrithione inhibits yeast growth through copper influx and inactivation of iron-sulfur proteins","volume":"55","author":"Reeder","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"12086","DOI":"10.1038\/s41598-018-30588-2","article-title":"Understanding the mechanism of action of the anti-dandruff agent zinc pyrithione against Malassezia restricta","volume":"8","author":"Park","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12223-011-0059-4","article-title":"Polyphasic characterization of \u201cAspergillus nidulans var. roseus\u201d ATCC 58397","volume":"56","author":"Nagy","year":"2011","journal-title":"Folia Microbiol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00253-020-11022-y","article-title":"Echinocandins: Structural diversity, biosynthesis, and development of antimycotics","volume":"105","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/hlca.19740570818","article-title":"Stoffwechselprodukte von mikroorganismen 143. Mitteilung. Echinocandin B, ein neuartiges Polypeptid-Antibioticum aus Aspergillus nidulans var. echinulatus: Isolierung und bausteine","volume":"57","author":"Benz","year":"1974","journal-title":"Helv. Chim. Acta"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1007\/s00253-013-4761-9","article-title":"Echinocandins: Production and applications","volume":"97","author":"Emri","year":"2013","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_304","first-page":"207","article-title":"Rezafungin: A \u03b2-(1,3)-D-glucan synthase inhibitor as antifungal drug derived from echinocandin B0","volume":"Volume 2","author":"Yu","year":"2026","journal-title":"Drug Discovery Stories"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1016\/S0040-4039(00)74618-1","article-title":"Struktur des Cyclopeptid-Antibiotikums SL 7810 (= Echinocandin B)","volume":"17","author":"Kuhn","year":"1976","journal-title":"Tetrahedron Lett."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0014-5793(84)81032-7","article-title":"Echinocandin inhibition of 1,3-\u03b2-D-glucan synthase from Candida albicans","volume":"173","author":"Kerridge","year":"1984","journal-title":"FEBS Lett."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"382","DOI":"10.7164\/antibiotics.42.382","article-title":"Deacylation of echinocandin B by Actinoplanes utahensis","volume":"42","author":"Boeck","year":"1989","journal-title":"J. Antibiot."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1517\/13543784.3.2.65","article-title":"Lipopeptide antifungal agents","volume":"3","author":"Balkovec","year":"1994","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1039\/C3NP70070D","article-title":"Discovery and development of first in class antifungal caspofungin (CANCIDAS\u00ae)\u2014A case study","volume":"31","author":"Balkovec","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1017\/S095375629800687X","article-title":"Reclassification of a pneumocandin-producing anamorph, Glarea lozoyensis gen. et sp. nov., previously identified as Zalerion arboricola","volume":"103","author":"Bills","year":"1999","journal-title":"Mycol. Res."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7164\/antibiotics.42.163","article-title":"L-671,329, a new antifungal agent. I. Fermentation and isolation","volume":"42","author":"Schwartz","year":"1989","journal-title":"J. Antibiot."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7164\/antibiotics.42.168","article-title":"L-671,329, a new antifungal agent. II. Structure determination","volume":"42","author":"Wichmann","year":"1989","journal-title":"J. Antibiot."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.7164\/antibiotics.45.1875","article-title":"Pneumocandins from Zalerion arboricola. III. Structure elucidation","volume":"45","author":"Hensens","year":"1992","journal-title":"J. Antibiot."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1021\/ol0261940","article-title":"Determination of the relative and absolute configuration of the dimethylmyristoyl side chain of pneumocandin B0 by asymmetric synthesis","volume":"4","author":"Leonard","year":"2002","journal-title":"Org. Lett."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1073\/pnas.87.15.5950","article-title":"Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors","volume":"87","author":"Schmatz","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_316","doi-asserted-by":"crossref","unstructured":"Cushion, M.T., Linke, M.J., Ashbaugh, A., Sesterhenn, T., Collins, M.S., Lynch, K., Brubaker, R., and Walzer, P.D. (2010). Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0008524"},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jmii.2016.03.008","article-title":"Caspofungin salvage therapy in Pneumocystis jirovecii pneumonia","volume":"50","author":"Lee","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-0043-1764375","article-title":"Pneumocystis jiroveci pneumonia: A review of management in human immunodeficiency virus (HIV) and non-HIV immunocompromised patients","volume":"13","author":"Ibrahim","year":"2023","journal-title":"Avicenna J. Med."},{"key":"ref_319","doi-asserted-by":"crossref","unstructured":"Buss, A.D., and Butler, M.S. (2009). Micafungin. Natural Product Chemistry for Drug Discovery, The Royal Society of Chemistry.","DOI":"10.1039\/9781847559890"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ja.2008.3","article-title":"Micafungin: A sulfated echinocandin","volume":"62","author":"Hashimoto","year":"2009","journal-title":"J. Antibiot."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.7164\/antibiotics.47.1084","article-title":"WF11899A, B and C, novel antifungal lipopeptides I. Taxonomy, fermentation, isolation and physico-chemical properties","volume":"47","author":"Iwamoto","year":"1994","journal-title":"J. Antibiot."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.7164\/antibiotics.47.1092","article-title":"WF11899A, B and C, novel antifungal lipopeptides II. Biological properties","volume":"47","author":"Iwamoto","year":"1994","journal-title":"J. Antibiot."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1021\/jm00017a012","article-title":"Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): Structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB","volume":"38","author":"Debono","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1517\/13543776.5.8.771","article-title":"Anti-infectives echinocandin lipopeptide antifungal agents: New agents and recent chemical modification studies","volume":"5","author":"Debono","year":"1995","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/14787210.5.1.45","article-title":"Anidulafungin: A new echinocandin for candidal infections","volume":"5","author":"Reboli","year":"2007","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_326","doi-asserted-by":"crossref","unstructured":"(2003). Anidulafungin. Drugs R&D, 4, 167\u2013173.","DOI":"10.2165\/00126839-200304030-00005"},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/cmi.12640","article-title":"CD101: A novel long-acting echinocandin","volume":"18","author":"Zhao","year":"2016","journal-title":"Cell. Microbiol."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"e01541-16","DOI":"10.1128\/AAC.01541-16","article-title":"Structure-activity relationships of a series of echinocandins and the discovery of CD101, a highly stable and soluble echinocandin with distinctive pharmacokinetic properties","volume":"61","author":"James","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1080\/14787210.2023.2240956","article-title":"Invasive Candida infection: Epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin","volume":"21","author":"Oliva","year":"2023","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-023-01891-8","article-title":"Rezafungin: First approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"ref_331","unstructured":"(2026, February 06). Mundipharma Acquires All Assets and Rights Related to REZZAYO\u00ae (Rezafungin), Reinforcing Continued Commitment to Management of Infectious Diseases and Specialty Care Therapeutic Area (Press Release 24 April 2024). Available online: https:\/\/www.mundipharma.com\/mundipharma-acquires-all-assets-and-rights-related-to-rezzayo."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/14756366.2022.2050224","article-title":"Echinocandins\u2014Structure, mechanism of action and use in antifungal therapy","volume":"37","author":"Chmielewska","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.tips.2024.02.007","article-title":"Targeting Fks1 proteins for novel antifungal drug discovery","volume":"45","author":"Kumar","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"118102","DOI":"10.1016\/j.ejmech.2025.118102","article-title":"Antifungal echinocandins: Historical discovery, comprehensive structure-activity relationships, resistance mechanisms and future developments","volume":"300","author":"Lang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/jac\/dkr142","article-title":"Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus","volume":"66","author":"Lewis","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"e00399-19","DOI":"10.1128\/AAC.00399-19","article-title":"Echinocandins for the treatment of invasive aspergillosis: From laboratory to bedside","volume":"63","author":"Aruanno","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41586-023-05856-5","article-title":"Structural and mechanistic insights into fungal \u03b2-1,3-glucan synthase FKS1","volume":"616","author":"Hu","year":"2023","journal-title":"Nature"},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"eadh7820","DOI":"10.1126\/sciadv.adh7820","article-title":"Structure of a fungal 1,3-\u03b2-glucan synthase","volume":"9","author":"Zhao","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_339","doi-asserted-by":"crossref","unstructured":"Liu, C.-Y., Zhang, L., Liu, S.-X., Lu, Y.-F., Li, C., and Pei, Y.-H. (2024). A review of the fernane-type triterpenoids as anti-fungal drugs. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1447450"},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1039\/D4NP00044G","article-title":"Fungerps: Discovery of the glucan synthase inhibitor enfumafungin and development of a new class of antifungal triterpene glycosides","volume":"41","author":"Vicente","year":"2024","journal-title":"Nat. Prod. Rep."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/AAC.44.2.368-377.2000","article-title":"Discovery of novel antifungal (1,3)-\u03b2-D-glucan synthase inhibitors","volume":"44","author":"Onishi","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0723-2020(00)80062-4","article-title":"The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species. Biological activity and taxonomy of the producing organisms","volume":"23","author":"Cabello","year":"2000","journal-title":"Syst. Appl. Microbiol."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1021\/ja9944296","article-title":"Isolation and structural determination of enfumafungin, a triterpene glycoside antifungal agent that is a specific inhibitor of glucan synthesis","volume":"122","author":"Schwartz","year":"2000","journal-title":"J. Am. Chem. Soc."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1111\/1462-2920.14333","article-title":"Enfumafungin synthase represents a novel lineage of fungal triterpene cyclases","volume":"20","author":"Kuhnert","year":"2018","journal-title":"Environ. Microbiol."},{"key":"ref_345","doi-asserted-by":"crossref","unstructured":"Rivero-Menendez, O., Soto-Debran, J.C., Cuenca-Estrella, M., and Alastruey-Izquierdo, A. (2021). In vitro activity of ibrexafungerp against a collection of clinical isolates of Aspergillus, including cryptic species and Cyp51A mutants, using EUCAST and CLSI Methodologies. J. Fungi, 7.","DOI":"10.3390\/jof7030232"},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1016\/j.bmcl.2012.05.031","article-title":"Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of \u03b2-1,3-glucan synthase","volume":"22","author":"Heasley","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1016\/j.bmcl.2015.10.011","article-title":"Novel orally active inhibitors of \u03b2-1,3-glucan synthesis derived from enfumafungin","volume":"25","author":"Apgar","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates","volume":"58","author":"Paderu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"127357","DOI":"10.1016\/j.bmcl.2020.127357","article-title":"MK-5204: An orally active \u03b2-1,3-glucan synthesis inhibitor","volume":"30","author":"Apgar","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"127661","DOI":"10.1016\/j.bmcl.2020.127661","article-title":"Ibrexafungerp: An orally active \u03b2-1,3-glucan synthesis inhibitor","volume":"32","author":"Apgar","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"e01324-23","DOI":"10.1128\/aac.01324-23","article-title":"In vitro activity of ibrexafungerp against clinically relevant echinocandin-resistant Candida strains","volume":"68","author":"Aldejohann","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"e00270-25","DOI":"10.1128\/msphere.00270-25","article-title":"Tn-seq screens in Candida glabrata treated with echinocandins and ibrexafungerp reveal pathways of antifungal resistance and cross-resistance","volume":"10","author":"Nickels","year":"2025","journal-title":"mSphere"},{"key":"ref_353","unstructured":"US FDA (2026, March 18). SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME\u00ae (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with a Non-Antibacterial \u00dflactam Drug Substance, Available online: https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/scynexis-issues-voluntary-nationwide-recall-brexafemmer-ibrexafungerp-tablets-due-potential-cross."},{"key":"ref_354","unstructured":"GSK Website (2026, March 18). GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (Ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection (Press Release 30 March 2023). Available online: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-and-scynexis-announce-an-exclusive-agreement-to-commercialise-and-further-develop-brexafemme-ibrexafungerp\/."},{"key":"ref_355","doi-asserted-by":"crossref","unstructured":"SCYNEXIS Website (2026, March 18). SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update (Press Release 4 March 2026). Available online: https:\/\/ir.scynexis.com\/news-events\/press-releases\/detail\/359\/scynexis-reports-full-year-2025-financial-results-and.","DOI":"10.1016\/j.fopow.2025.03.013"},{"key":"ref_356","doi-asserted-by":"crossref","unstructured":"Quind\u00f3s, G., Miranda-Cadena, K., San-Mill\u00e1n, R., Borroto-Esoda, K., Cant\u00f3n, E., Linares-Sicilia, M.J., Hamprecht, A., Montesinos, I., Tortorano, A.M., and Prigitano, A. (2022). In vitro antifungal activity of ibrexafungerp (SCY-078) against contemporary blood isolates from medically relevant species of Candida: A European study. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.906563"},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"1154.e5","DOI":"10.1016\/j.cmi.2022.04.003","article-title":"\u0394F659 and F659S substitutions at the HS1 of FKS2 gene, along with E655A and W715L upstream and downstream substitutions, correlate with high ibrexafungerp MICs against Candida glabrata","volume":"28","author":"Mesquida","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"myad072","DOI":"10.1093\/mmy\/myad072","article-title":"Yeasts from blood cultures in the wake of the COVID-19 pandemic in a tertiary care hospital: Shift in species epidemiology, steady low antifungal resistance and full in vitro ibrexafungerp activity","volume":"61","author":"Mesquida","year":"2023","journal-title":"Med. Mycol."},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"e12576","DOI":"10.1111\/dth.12576","article-title":"The role of zinc in the treatment of acne: A review of the literature","volume":"31","author":"Cervantes","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/jid.1938.25","article-title":"The effects of hydrogen ion concentration, fatty acids and vitamin C on the growth of fungi","volume":"1","author":"Peck","year":"1938","journal-title":"J. Investig. Dermatol."},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11046-016-0073-9","article-title":"Toward a novel multilocus phylogenetic taxonomy for the dermatophytes","volume":"182","author":"Dukik","year":"2017","journal-title":"Mycopathologia"},{"key":"ref_362","first-page":"391","article-title":"Recherches sur l\u2019action de divers acides et sels acides sur le d\u00e9veloppement de l\u2019Aspergillus niger","volume":"27","author":"Kiesel","year":"1913","journal-title":"Ann. Inst. Pasteur"},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2621.1939.tb17151.x","article-title":"Fungistatic properties of the fatty acids and possible biochemical significance","volume":"4","author":"Hoffman","year":"1939","journal-title":"J. Food Sci."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1439-0507.1993.tb00687.x","article-title":"Fungitoxicity of fatty acids against dermatophytes","volume":"36","author":"Garg","year":"1993","journal-title":"Mycoses"},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11046-021-00550-4","article-title":"Reassessing the use of undecanoic acid as a therapeutic strategy for treating fungal infections","volume":"186","author":"Rossi","year":"2021","journal-title":"Mycopathologia"},{"key":"ref_366","first-page":"422","article-title":"Sodium caprylate. A new and effective treatment for dermatomycosis of the feet","volume":"LXXVII","author":"Keeney","year":"1945","journal-title":"Bull. Johns Hopkins Hosp."},{"key":"ref_367","doi-asserted-by":"crossref","unstructured":"Balderrama-G\u00f3mez, A., Mu\u00f1oz-P\u00e9rez, V.M., Ortiz, M.I., Cari\u00f1o-Cort\u00e9s, R., Castro-Rosas, J., Betanzos, A., Fern\u00e1ndez-Mart\u00ednez, E., and Castillo-Ju\u00e1rez, I. (2025). Using caprylic acid for the prevention and treatment of Helicobacter pylori infection and gastric cancer: A review. Metabolites, 15.","DOI":"10.3390\/metabo15090629"},{"key":"ref_368","first-page":"417","article-title":"Propionate and undecylenate ointments in the treatment of tinea pedis and an in vitro comparison of their fungistatic and antibacterial effects with other ointments","volume":"LXXV","author":"Keeney","year":"1944","journal-title":"Bull. Johns Hopkins Hosp."},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archderm.1945.01510270024004","article-title":"Undecylenic acid in the treatment of dermatomycosis","volume":"52","author":"Shapiro","year":"1945","journal-title":"Arch. Derm. Syphilol."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archderm.1947.01520030084013","article-title":"Undecylenic and propionic acids in the prevention and treatment of dermatophytosis","volume":"55","author":"Sulzberger","year":"1947","journal-title":"Arch. Derm. Syphilol."},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-4362.1980.tb01986.x","article-title":"Short chain fatty acids in the treatment of dermatophytoses","volume":"19","author":"Lyddon","year":"1980","journal-title":"Int. J. Dermatol."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/archderm.1983.01650280079021","article-title":"Commentary: Undecylenic acid and fungous infections","volume":"119","author":"Landau","year":"1983","journal-title":"Arch. Dermatol."},{"key":"ref_373","unstructured":"(2026, March 24). Justia Website. Pennwalt Corp. v. Becton, Dickinson & Co., 434 F. Supp. 758 (D.N.J. 1977). Available online: https:\/\/law.justia.com\/cases\/federal\/district-courts\/FSupp\/434\/758\/1417268\/."},{"key":"ref_374","first-page":"641","article-title":"Variations in the essential oil composition of Persea bombycina (King ex Hook f.) Kost and its effect on muga silkworm (Antheraea assama Ww)\u2014A new report","volume":"42B","author":"Choudhury","year":"2003","journal-title":"Indian J. Chem. Sect. B Org. Chem. Incl. Med. Chem."},{"key":"ref_375","first-page":"102","article-title":"Analysis on fat-soluble constituents in flowers of Tibetan medicinal plants of three Gentiana species by GC-MS","volume":"19","author":"Lin","year":"2013","journal-title":"Chin. J. Exp. Tradit. Med. Formulae"},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1039\/jr9470000753","article-title":"143. Reactions of carbinols in the presence of alkali. Part II. The scission of ricinoleic acid","volume":"150","author":"Hargreaves","year":"1947","journal-title":"J. Chem. Soc."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"e14008","DOI":"10.1002\/ep.14008","article-title":"A comprehensive review of castor oil-derived renewable and sustainable industrial products","volume":"42","author":"Singh","year":"2023","journal-title":"Environ. Prog. Sustain. Energy"},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archderm.1947.01520110047007","article-title":"Propionate-caprylate mixtures in the treatment of dermatomycoses: With a review of fatty acid therapy in general","volume":"56","author":"Peck","year":"1947","journal-title":"Arch. Derm. Syphilol."},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"9903","DOI":"10.1021\/acs.jafc.5c14438","article-title":"Pelargonic acid: From historical uses to future perspectives in sustainable agriculture","volume":"74","author":"Preisler","year":"2026","journal-title":"J. Agric. Food Chem."},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archderm.1959.01560220092019","article-title":"Antimycotic cream and powder. Clinical evaluation","volume":"80","author":"Bereston","year":"1959","journal-title":"Arch. Dermatol."},{"key":"ref_381","first-page":"1000484","article-title":"Food industry applications and synthesis methods of pelargonic acid","volume":"14","author":"Flazily","year":"2023","journal-title":"J. Chem. Eng. Process Technol."},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/BF00182806","article-title":"Effects of ethanol, octanoic and decanoic acids on fermentation and the passive influx of protons through the plasma membrane of Saccharomyces cerevisiae","volume":"38","author":"Stevens","year":"1993","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1439-0507.2001.00609.x","article-title":"Antifungal activities of pelargonic and capric acid on Microsporum gypseum","volume":"44","author":"Chadeganipour","year":"2001","journal-title":"Mycoses"},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1128\/AAC.45.11.3209-3212.2001","article-title":"In vitro killing of Candida albicans by fatty acids and monoglycerides","volume":"45","author":"Bergsson","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_385","doi-asserted-by":"crossref","unstructured":"Bhattacharyya, A., Sinha, M., Singh, H., Patel, R.S., Ghosh, S., Sardana, K., Ghosh, S., and Sengupta, S. (2020). Mechanistic insight into the antifungal effects of a fatty acid derivative against drug-resistant fungal infections. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.02116"},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/1751-7915.13710","article-title":"Antibiofilm and antifungal activities of medium-chain fatty acids against Candida albicans via mimicking of the quorum-sensing molecule farnesol","volume":"14","author":"Lee","year":"2021","journal-title":"Microb. Biotechnol."},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1128\/AAC.44.10.2873-2875.2000","article-title":"Undecylenic acid inhibits morphogenesis of Candida albicans","volume":"44","author":"McLain","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5414\/CP202460","article-title":"Antifungal effects of undecylenic acid on the biofilm formation of Candida albicans","volume":"54","author":"Shi","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/00362178285380271","article-title":"Effect of undecanoic acid on the production of exocellular lipolytic and keratinolytic enzymes by undecanoic acid-sensitive and -resistant strains of Trichophyton rubrum","volume":"20","author":"Das","year":"1982","journal-title":"Sabouraudia"},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00437411","article-title":"Effect of undecanoic acid on lipid composition of Trichophyton rubrum","volume":"83","author":"Das","year":"1983","journal-title":"Mycopathologia"},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1038\/s41598-018-20738-x","article-title":"Transcriptome-wide survey of gene expression changes and alternative splicing in Trichophyton rubrum in response to undecanoic acid","volume":"8","author":"Mendes","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_392","doi-asserted-by":"crossref","unstructured":"Persinoti, G.F., de Aguiar Peres, N.T., Jacob, T.R., Rossi, A., V\u00eancio, R.Z., and Martinez-Rossi, N.M. (2014). RNA-sequencing analysis of Trichophyton rubrum transcriptome in response to sublethal doses of acriflavine. BMC Genom., 15.","DOI":"10.1186\/1471-2164-15-S7-S1"},{"key":"ref_393","doi-asserted-by":"crossref","unstructured":"Martins, M.P., Silva, L.G., Rossi, A., Sanches, P.R., Souza, L.D.R., and Martinez-Rossi, N.M. (2019). Global analysis of cell wall genes revealed putative virulence factors in the dermatophyte Trichophyton rubrum. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.02168"},{"key":"ref_394","doi-asserted-by":"crossref","unstructured":"Lopes, M.E.R., Bitencourt, T.A., Sanches, P.R., Martins, M.P., Oliveira, V.M., Rossi, A., and Martinez-Rossi, N.M. (2022). Alternative splicing in Trichophyton rubrum occurs in efflux pump transcripts in response to antifungal drugs. J. Fungi, 8.","DOI":"10.3390\/jof8080878"},{"key":"ref_395","first-page":"291","article-title":"Effect of undecanoic acid on the production of esterases and lipases by Aspergillus nidulans","volume":"55","author":"Madurro","year":"2005","journal-title":"Ann. Microbiol."},{"key":"ref_396","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10528-008-9170-x","article-title":"A single amino acid substitution in one of the lipases of Aspergillus nidulans confers resistance to the antimycotic drug undecanoic acid","volume":"46","author":"Prade","year":"2008","journal-title":"Biochem. Genet."},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"e00402-19","DOI":"10.1128\/mSphere.00402-19","article-title":"Susceptibility to medium-chain fatty acids is associated with trisomy of chromosome 7 in Candida albicans","volume":"4","author":"Ma","year":"2019","journal-title":"mSphere"},{"key":"ref_398","doi-asserted-by":"crossref","unstructured":"Muthamil, S., Balasubramaniam, B., Balamurugan, K., and Pandian, S.K. (2018). Synergistic effect of quinic acid derived from Syzygium cumini and undecanoic acid against Candida spp. biofilm and virulence. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.02835"},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/jid.1955.105","article-title":"Experimental studies on drug resistance of dermatophytes: I. The development of drug resistance of Trichophyton mentagrophytes and Microsporum lanosum to undecylenic acid and 2-dimethylamino-6-(\u03b2-di-ethylaminoethoxy) benzothiazole dihydrochloride (Asterol)","volume":"25","author":"Grunberg","year":"1955","journal-title":"J. Investig. Dermatol."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/ja01573a087","article-title":"The synthesis of 5-fluoropyrimidines","volume":"79","author":"Duschinsky","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"ref_401","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/179663a0","article-title":"Fluorinated pyrimidines, a new class of tumour-inhibitory compounds","volume":"179","author":"Heidelberger","year":"1957","journal-title":"Nature"},{"key":"ref_402","first-page":"305","article-title":"Studies on fluorinated pyrimidines: II. Effects on transplanted tumors","volume":"18","author":"Heidelberger","year":"1958","journal-title":"Cancer Res."},{"key":"ref_403","first-page":"566","article-title":"Chemotherapeutic activity of 5-fluorocytosine","volume":"1963","author":"Grunberg","year":"1964","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jama.1968.03150040042009","article-title":"Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine: A new antifungal agent","volume":"206","author":"Tassel","year":"1968","journal-title":"JAMA"},{"key":"ref_405","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_406","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-4362.1971.tb01695.x","article-title":"Treatment of chromomycosis with 5-fluorocytosine","volume":"10","author":"Lopes","year":"1971","journal-title":"Int. J. Dermatol."},{"key":"ref_407","unstructured":"FDA (2026, March 13). Report Website. NDC 0187-3554, Ancobon. Available online: https:\/\/fda.report\/NDC\/0187-3554."},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acs.oprd.6b00420","article-title":"One-step continuous flow synthesis of antifungal WHO essential medicine flucytosine using fluorine","volume":"21","author":"Harsanyi","year":"2017","journal-title":"Org. Process Res. Dev."},{"key":"ref_409","first-page":"20499361231161387","article-title":"Flucytosine and its clinical usage","volume":"10","author":"Sigera","year":"2023","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_410","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/myc.13528","article-title":"Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not?","volume":"66","author":"Zhao","year":"2023","journal-title":"Mycoses"},{"key":"ref_411","doi-asserted-by":"crossref","unstructured":"Delma, F.Z., Al-Hatmi, A.M.S., Br\u00fcggemann, R.J.M., Melchers, W.J.G., de Hoog, S., Verweij, P.E., and Buil, J.B. (2021). Molecular mechanisms of 5-fluorocytosine resistance in yeasts and filamentous fungi. J. Fungi, 7.","DOI":"10.3390\/jof7110909"},{"key":"ref_412","first-page":"407","article-title":"Flucytosine treatment and resistance mechanisms","volume":"Volume 1","author":"Mayers","year":"2017","journal-title":"Antimicrobial Drug Resistance: Mechanisms of Drug Resistance"},{"key":"ref_413","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1038\/s41467-021-23745-1","article-title":"Moderate levels of 5-fluorocytosine cause the emergence of high frequency resistance in cryptococci","volume":"12","author":"Chang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_414","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1128\/AAC.48.11.4377-4386.2004","article-title":"Molecular mechanisms of primary resistance to flucytosine in Candida albicans","volume":"48","author":"Hope","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_415","doi-asserted-by":"crossref","unstructured":"Costa, C., Ponte, A., Pais, P., Santos, R., Cavalheiro, M., Yaguchi, T., Chibana, H., and Teixeira, M.C. (2015). New mechanisms of flucytosine resistance in C. glabrata unveiled by a chemogenomics analysis in S. cerevisiae. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135110"},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"e03451-22","DOI":"10.1128\/mbio.03451-22","article-title":"Factors influencing the nitrogen-source dependent flucytosine resistance in Cryptococcus species","volume":"14","author":"Yang","year":"2023","journal-title":"mBio"},{"key":"ref_417","unstructured":"World Health Organization (2026, September 08). Antifungal Agents in Clinical and Preclinical Development (1 April 2025). Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240105140."},{"key":"ref_418","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1039\/D5NP00031A","article-title":"Natural product-derived compounds in clinical trials and drug approvals","volume":"43","author":"Butler","year":"2026","journal-title":"Nat. Prod. Rep."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/9\/938\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:03:59Z","timestamp":1790093039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/9\/938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":418,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["antibiotics15090938"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15090938","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}